Kala Visvanathan

22.0k total citations · 2 hit papers
191 papers, 7.8k citations indexed

About

Kala Visvanathan is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Kala Visvanathan has authored 191 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 53 papers in Cancer Research and 44 papers in Genetics. Recurrent topics in Kala Visvanathan's work include Cancer Risks and Factors (43 papers), Estrogen and related hormone effects (25 papers) and BRCA gene mutations in cancer (21 papers). Kala Visvanathan is often cited by papers focused on Cancer Risks and Factors (43 papers), Estrogen and related hormone effects (25 papers) and BRCA gene mutations in cancer (21 papers). Kala Visvanathan collaborates with scholars based in United States, Finland and Ireland. Kala Visvanathan's co-authors include Patricia Hartge, Linda Sharp, Thomas I. Barron, Amy Berrington de González, Martha S. Linet, Alpa V. Patel, Charles E. Matthews, Elisabete Weiderpass, Steven C. Moore and Kathleen Bennett and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Kala Visvanathan

179 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leisure Time Physical Activity and Mortality

2015 978 citations Kala Visvanathan et al. profile →
Leisure Time Physical Activity of Moderate to Vigorous Intensity and Mortality: A Large Pooled Cohort Analysis

2012 461 citations Kala Visvanathan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kala Visvanathan United States	43	2.2k	1.9k	1.7k	1.1k	1.1k	191	7.8k
Daehee Kang South Korea	54	2.2k 1.0×	3.2k 1.7×	2.1k 1.3×	870 0.8×	1.7k 1.6×	332	9.7k
Konstantinos K. Tsilidis Greece	41	1.7k 0.8×	1.5k 0.8×	955 0.6×	938 0.8×	661 0.6×	162	7.0k
Marilyn L. Kwan United States	53	4.6k 2.1×	1.4k 0.7×	1.5k 0.9×	1.8k 1.6×	883 0.8×	197	8.9k
Roger L. Milne Australia	44	2.0k 0.9×	1.8k 0.9×	943 0.6×	617 0.6×	1.6k 1.5×	246	5.9k
Yin Cao United States	41	2.4k 1.1×	1.7k 0.9×	1.2k 0.7×	1.1k 1.0×	398 0.4×	249	7.4k
Jane Christensen Denmark	50	2.1k 0.9×	1.7k 0.9×	634 0.4×	1.1k 1.0×	906 0.8×	227	7.9k
Kathy J. Helzlsouer United States	58	2.5k 1.1×	2.6k 1.3×	1.9k 1.2×	712 0.6×	2.0k 1.8×	156	9.9k
Christopher A. Haiman United States	48	2.1k 1.0×	2.9k 1.5×	1.4k 0.9×	894 0.8×	2.9k 2.7×	264	8.8k
Xiao Ou Shu United States	55	2.5k 1.1×	3.0k 1.6×	1.6k 0.9×	1.3k 1.1×	1.2k 1.2×	184	9.9k
Britton Trabert United States	41	1.8k 0.8×	2.0k 1.0×	1.5k 0.9×	355 0.3×	823 0.8×	173	7.7k

Countries citing papers authored by Kala Visvanathan

Since Specialization

Citations

This map shows the geographic impact of Kala Visvanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kala Visvanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kala Visvanathan more than expected).

Fields of papers citing papers by Kala Visvanathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kala Visvanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kala Visvanathan. The network helps show where Kala Visvanathan may publish in the future.

Co-authorship network of co-authors of Kala Visvanathan

This figure shows the co-authorship network connecting the top 25 collaborators of Kala Visvanathan. A scholar is included among the top collaborators of Kala Visvanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kala Visvanathan. Kala Visvanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Visvanathan, Kala, Deborah K. Armstrong, Jin He, et al.. (2025). Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. JCO Precision Oncology. 9(9). e2400494–e2400494. 1 indexed citations

Visvanathan, Kala. (2024). USPSTF recommends biennial mammography for breast cancer screening in women aged 40 to 74 y. Annals of Internal Medicine. 177(10). JC110–JC110.

Wu, Tzu-I, Rebecca L. Stone, Tian‐Li Wang, et al.. (2024). Salpingectomy for ectopic pregnancy reduces ovarian cancer risk—a nationwide study. JNCI Cancer Spectrum. 8(3). 1 indexed citations

Scharpf, Robert B., et al.. (2023). Potential utility of risk stratification for multicancer screening with liquid biopsy tests. npj Precision Oncology. 7(1). 39–39. 3 indexed citations

Karia, Pritesh S., Yongmei Huang, Parisa Tehranifar, et al.. (2022). Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States. American Journal of Obstetrics and Gynecology. 227(2). 257.e1–257.e22. 10 indexed citations

Deng, Zhengyi, et al.. (2022). Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study. npj Breast Cancer. 8(1). 82–82. 9 indexed citations

Visvanathan, Kala, Leslie Cope, Mary Jo Fackler, et al.. (2022). Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. Clinical Cancer Research. 29(4). 784–790. 12 indexed citations

Deng, Zhengyi, et al.. (2022). Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy. JNCI Journal of the National Cancer Institute. 115(3). 279–287. 4 indexed citations

Reiter–Brennan, Cara, Omar Dzaye, Mouaz H. Al‐Mallah, et al.. (2021). Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project. Cancer. 127(11). 1864–1870. 9 indexed citations

10.

Karia, Pritesh S., Corinne E. Joshu, & Kala Visvanathan. (2021). Association of Oophorectomy and Fat and Lean Body Mass: Evidence from a Population-Based Sample of U.S. Women. Cancer Epidemiology Biomarkers & Prevention. 30(7). 1424–1432. 6 indexed citations

11.

Karia, Pritesh S., Corinne E. Joshu, & Kala Visvanathan. (2021). Uptake and Predictors of Opportunistic Salpingectomy for Ovarian Cancer Risk Reduction in the United States. Cancer Prevention Research. 14(12). 1101–1110. 11 indexed citations

12.

Fackler, Mary Jo, Soonweng Cho, Leslie Cope, et al.. (2020). DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. npj Breast Cancer. 6(1). 3–3. 21 indexed citations

13.

Ramin, Cody, Zihe Zheng, Avonne E. Connor, et al.. (2020). All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort. JNCI Journal of the National Cancer Institute. 113(2). 137–145. 85 indexed citations

14.

Visvanathan, Kala, Carol J. Fabian, Elissa Bantug, et al.. (2019). Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 37(33). 3152–3165. 117 indexed citations

15.

Visvanathan, Kala, Patricia Shaw, Asli Bahadirli-Talbott, et al.. (2018). Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prevention Research. 11(11). 697–706. 49 indexed citations

16.

Gross, Amy L., et al.. (2015). Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1262–1269. 39 indexed citations

17.

Barron, Thomas I., Laura Murphy, Chris Brown, et al.. (2015). De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I–III Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(6). 898–904. 21 indexed citations

18.

Kobayashi, Yusuke, Hiroyasu Kashima, Ren‐Chin Wu, et al.. (2015). Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clinical Cancer Research. 21(20). 4652–4662. 49 indexed citations

19.

Fackler, Mary Jo, Zoila A. Lopez‐Bujanda, Christopher B. Umbricht, et al.. (2014). Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research. 74(8). 2160–2170. 118 indexed citations

20.

Barron, Thomas I., Roisín M. Connolly, Linda Sharp, Kathleen Bennett, & Kala Visvanathan. (2011). Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. 29(19). 2635–2644. 428 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact